title: Ovarian follicular development and oocyte quality in anestrous ewes treated with melatonin, a controlled internal drug release (CIDR) device and follicle stimulating hormone.
abstract: The objective of the current study was to determine the effects of hormonal treatments on ovarian follicular development and oocyte quality in anestrous ewes. Multiparous crossbred (RambouilletxTarghee) ewes were given melatonin implants (MEL) and/or controlled internal drug release (CIDR) devices in conjunction with follicle stimulating hormone (FSH) during anestrus (March-May). In Experiment 1, ewes (n=25) were assigned randomly to four groups (n=4-7/group) in a 2x2 factorial arrangement [+/-MEL and +/-CIDR], resulting in Control (no treatment), CIDR, MEL, and MEL/CIDR groups, respectively. Ewes received an implant containing 18 mg of melatonin (Melovine) on Day 42 and/or a CIDR from Days 7 to 2 (Day 0: oocyte collection). In Experiment 2, ewes (n=12) were assigned randomly to two groups (n=6/group; 1CIDR or 2CIDR) and received the same type of melatonin implant on Day 60. All ewes received a CIDR device from Days -22 to -17 and 2CIDR ewes received an additional CIDR device from Days -10 to -2. In both experiments, ewes were given FSH im twice daily (morning and evening) on Days -2 and -1 (Day -2: 5 units/injection; Day -1: 4 units/injection). On the morning of Day 0, ovaries were removed, follicles>or=1 mm were counted, and oocytes were collected. Thereafter oocytes were matured and fertilized in vitro. In Experiment 1, the number of visible follicles and the rates of oocyte recovery and in vitro maturation were similar (P>0.10) for Control, CIDR, MEL and MEL/CIDR (overall 29.7+/-2.9%, 89.9+/-7.1% and 95.0+/-2.0%, respectively). The rates of in vitro fertilization (IVF) were lower (P<0.01) for CIDR and MEL/CIDR than for Control and MEL groups (10.3% and 10.1% versus 20.0% and 18.5%, respectively). In Experiment 2, the number of visible follicles, and the rates of oocyte recovery and in vitro maturation were similar (P>0.10) for 1CIDR and 2CIDR groups (overall 27.3+/-3.2%, 92.1+/-2.7% and 90.2+/-1.9%, respectively). However, the rates of IVF were lower (P<0.01) for 2CIDR than 1CIDR group (30.2% versus 58.0%, respectively). In summary, when treatment with P4 commenced only 2 d before oocyte collection, rates of IVF were reduced in both experiments. Therefore, progestin treatment protocols used in ovine IVF programs should be carefully designed to minimize adverse effects on fertilization rates. In addition, melatonin treatment did not affect follicular development and oocyte quality for anestrous ewes.
authors.affiliation: Department of Animal and Range Sciences, North Dakota State University, Fargo, ND 58105-5727, USA.
authors.forename: Justin S
authors.initials: JS
authors.lastname: Luther
authors.forename: Dale A
authors.initials: DA
authors.lastname: Redmer
authors.forename: Lawrence P
authors.initials: LP
authors.lastname: Reynolds
authors.forename: Jong Tae
authors.initials: JT
authors.lastname: Choi
authors.forename: Disha
authors.initials: D
authors.lastname: Pant
authors.forename: Chainarong
authors.initials: C
authors.lastname: Navanukraw
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Arnold
authors.forename: Abraham N
authors.initials: AN
authors.lastname: Scheaffer
authors.forename: Pawel
authors.initials: P
authors.lastname: Borowicz
authors.forename: James D
authors.initials: JD
authors.lastname: Kirsch
authors.forename: Robert M
authors.initials: RM
authors.lastname: Weigl
authors.forename: Kim C
authors.initials: KC
authors.lastname: Kraft
authors.forename: Anna T
authors.initials: AT
authors.lastname: Grazul-Bilska
mesh_terms: D000780:Anestrus; D000818:Animals; D016503:Drug Delivery Systems / Q000295:instrumentation; D004343:Drug Implants; D005260:Female; D005307:Fertilization in Vitro / Q000662:veterinary; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage*; D008550:Melatonin / Q000008:administration & dosage*; D009865:Oocytes / Q000502:physiology*; D006080:Ovarian Follicle / Q000033:anatomy & histology / Q000254:growth & development*; D011374:Progesterone / Q000008:administration & dosage; D012756:Sheep / Q000502:physiology*
chemical_list: D004343:Drug Implants; D011374:Progesterone; D005640:Follicle Stimulating Hormone; D008550:Melatonin